Catalyst Biosciences Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Catalyst Biosciences ha aumentado sus beneficios a una tasa media anual de 6.2%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 12.7%. Los ingresos han ido disminuyendo a una tasa media de 5.7% al año.

Información clave

6.2%

Tasa de crecimiento de los beneficios

28.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-5.7%
Rentabilidad financiera	-1,257.9%
Margen neto	n/a
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Jun 03

Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

May 18

Catalyst Biosciences EPS misses by $0.12, beats on revenue

May 06

Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

Mar 09

We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Feb 01

Catalyst Biosciences announces closing of $50M capital raise

Jan 29

Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

Dec 28

Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients

Dec 02

What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Dec 02

Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow

Nov 18

Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next

Nov 14

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Catalyst Biosciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:CBIO Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 23	0	-44	13
30 Jun 23	0	-48	15
31 Mar 23	0	7	16
31 Dec 22	1	-8	17
30 Sep 22	3	12	17
30 Jun 22	6	-8	17
31 Mar 22	7	-80	18
31 Dec 21	7	-88	19
30 Sep 21	7	-87	19
30 Jun 21	6	-77	18
31 Mar 21	6	-75	18
31 Dec 20	21	-56	16
30 Sep 20	19	-51	15
30 Jun 20	18	-48	15
31 Mar 20	16	-44	13
31 Dec 19	0	-55	13
30 Sep 19	0	-52	14
30 Jun 19	0	-47	13
31 Mar 19	0	-40	13
31 Dec 18	0	-30	12
30 Sep 18	0	-25	11
30 Jun 18	1	-23	11
31 Mar 18	1	-26	11
31 Dec 17	1	-26	10
30 Sep 17	1	-24	10
30 Jun 17	1	-22	10
31 Mar 17	1	-17	9
31 Dec 16	0	-17	9
30 Sep 16	0	-18	10
30 Jun 16	0	-19	10
31 Mar 16	1	-15	10
31 Dec 15	2	-15	10
30 Sep 15	2	-11	8
30 Jun 15	3	-7	6
31 Mar 15	2	-8	5
31 Dec 14	2	-7	4
31 Dec 13	1	-10	4

Ingresos de calidad: CBIO actualmente no es rentable.

Margen de beneficios creciente: CBIO actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CBIO no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 6.2% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CBIO en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CBIO no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: CBIO tiene una rentabilidad financiera negativa (-1257.95%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Catalyst Biosciences Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings: EPS misses analyst expectations

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold US$284k worth of stock

Insider recently sold US$506k worth of stock

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences declares special one-time dividend of $1.43

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences plans to distribute $65M cash to stockholders

Insider recently bought US$936k worth of stock

JEC II Associates Engages in Discussions with Catalyst Biosciences

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Consensus revenue estimates fall by 86%

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Consensus revenue estimates increase by 16%

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

Price target decreased to US$3.00

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky

Circling Back On Catalyst Biosciences

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

Price target decreased to US$13.25

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Consensus revenue estimates increase to US$4.10m

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

Consensus forecasts updated

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Catalyst Biosciences EPS misses by $0.12, beats on revenue

Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

Revenue and earnings beat expectations

Price target lowered to US$17.00

Price target lowered to US$18.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Catalyst Biosciences announces closing of $50M capital raise

Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

New 90-day high: US$7.29

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients

What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Desglose de ingresos y gastos
Beta